The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 46 | 24.2x | 20.1x | Near average | |
Growth | 34 | 6.6% | 5.6% | Below average | |
Quality | 51 | 9.1% | 7.6% | Near average | |
Safety | 53 | 2.1x | 0.4x | Near average | |
Capital Return | 32 | 2.80% | 2.19% | Below average | |
Momentum | 11 | — | — | Below average | |
Sentiment | 51 | — | — | Near average |
Abbott Laboratories is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Abbott Laboratories shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Recent data indicates a slight decline in analyst optimism toward Abbott Laboratories stock, as the average price target decreased by 2.09% over the past 30 days to reach $128.71. This decline coincided with a downgrade of the stock by Daiwa to 'Neutral' in late April, reflecting increasing caution despite the current price (88.835) remaining below the lowest analyst price target ($92).
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.